课题基金 / 基金详情

LACTOFERRIN EXPRESSION IN TRANSGENIC MICE

LACTOFERRIN EXPRESSION IN TRANSGENIC MICE
转基因小鼠中乳铁蛋白的表达
批准号:
2673879
负责人:
MARGARET Cobb NEVILLE
金额:
$24.71万
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-04-01 至 2000-03-31

项目摘要

项目成果

MARGARET Cobb NEVILLE的其他基金

相似基金

相关文献

中文摘要
翻译
乳铁蛋白是一种多功能的非血红素铁结合蛋白,发现于 在牛奶中浓度高,一些粘膜分泌物,并在特定情况下 多形核白细胞颗粒。我们知道很多关于 乳铁蛋白的结构,铁结合,对病原体和 与各种类型的细胞结合。我们真正不明白的是 分子的生理作用,特别是在牛奶和 乳腺。乳铁蛋白提供了母乳中25%的蛋白质, 然而,配方奶粉喂养的婴儿,他们的牛奶中没有乳铁蛋白, 看起来做得很好。婴儿添加乳铁蛋白的技术能力 配方正在迅速开发。问题是,这是必要的还是 在什么情况下是有益的?目前的方法使用老鼠作为 一个模型系统来研究这种优雅的生理作用 分子。这种模式系统比饮食或配方奶粉更有优势。 补充剂将改变剂量的乳铁蛋白输送到 新生儿从出生的时候起,就在天然的、物种特有的牛奶中。 我们的具体实验方法将在小鼠身上使用转基因技术。 提供对双重假设的关键测试,这些假设包括: (1)乳铁蛋白在人类新生儿发育中的主要作用 I)具体地通过将多余的铁从 胃肠道,ii)刺激肠道成熟和 3)减少潜在细菌病原体的生长。 (2)在乳腺本身,乳铁蛋白可以预防感染 以及分泌停滞期的炎症,例如妊娠晚期, 复旧和乳房炎。 为了检验这些假设,我们将首先检查 人乳铁蛋白在小鼠乳汁中的过表达对新生儿发育的影响 并利用已有的转基因小鼠保持铁平衡。到时候我们会的 建立过表达同源乳铁蛋白的转基因小鼠 了解该分子对物种的特定影响。最后,我们 将开发技术以获得乳房特异性抑制 乳铁蛋白在乳汁发生和退化过程中的合成。 在缺乏大量活性重组乳铁蛋白供应的情况下 概述的战略是唯一可以同时满足人类和 对新生动物大量使用的同源乳铁蛋白。如果 抑制方法是成功的,我们还将能够定义 乳铁蛋白缺乏对乳腺和乳腺的影响 新生儿。所提出的转基因技术的力量是 它们是特定于乳腺的,并解决了长期的生理学问题 母亲和婴儿中的乳铁蛋白。
英文摘要
Lactoferrin is a multifunctional, non-heme iron-binding protein found in high concentration in milk, some mucosal secretions, and in specific granules of polymorphonuclear leukocytes. We know a great deal about lactoferrin structure, iron binding, effects on pathogenic agents and binding to various types of cells. What we really do not understand is the physiological role of the molecule, particularly in the milk and mammary gland. Lactoferrin provides 25% of the protein in human milk, yet formula-fed infants, who receive no lactoferrin in their milk, seemingly do well. The technical capacity to add lactoferrin to infant formula is rapidly being developed. The question is, is it necessary or beneficial and under what conditions? The present approach uses mice as a model system to investigate the physiological role of this elegant molecule. This model system has the advantage over dietary or formula supplementation that altered doses of lactoferrin are delivered to the neonate from the time of birth and in the natural, species specific milk. Our specific experimental approach will use transgenic technology in mice to provide critical tests of the dual hypotheses that: (1) The major roles of lactoferrin in neonatal development in the human are i) to regulate iron balance specifically by removing excess iron from the gastrointestinal tract, ii) to stimulate intestinal maturation and iii) to decrease growth of potential bacterial pathogens. (2) In the mammary gland itself lactoferrin protects against infection and inflammation during periods of secretory stasis, e.g. late pregnancy, involution and mastitis. To test these hypotheses we will first examine the effects of overexpression of human lactoferrin in mouse milk on neonatal development and iron balance using transgenic mice already available. We will then create transgenic mice overexpressing homologous lactoferrin in order to understand the species-specific effects of the molecule. Finally, we will develop technology to obtain mammary-specific inhibition of lactoferrin synthesis during lactogenesis and involution. In the absence of large supplies of active, recombinant lactoferrin the strategy outlined is the only one that can supply both human and homologous lactoferrin in large quantities to neonatal animals. If the inhibition approach is successful, we will in addition be able to define the effects of lactoferrin deficiency both in the mammary gland and in the neonate. The power of the transgenic techniques proposed are that they are mammary specific and address the long term physiology of lactoferrin n both mother and infant.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ADMINISTRATIVE CORE
  • 批准号:
    7018045
  • 项目类别:
  • 资助金额:
    $5.41万
  • 财政年份:
    2005
  • 负责人:
    MARGARET Cobb NEVILLE
  • 依托单位:
INTERACTION OF GLUCOSE AND LIPID WITH CELL SURVIVAL IN LACTATION
  • 批准号:
    7018025
  • 项目类别:
  • 资助金额:
    $23.42万
  • 财政年份:
    2005
  • 负责人:
    MARGARET Cobb NEVILLE
  • 依托单位:
Progesterone Withdrawal/Tight Junction Closure--Pregnant
  • 批准号:
    6602426
  • 项目类别:
  • 资助金额:
    $15.0万
  • 财政年份:
    2002
  • 负责人:
    MARGARET Cobb NEVILLE
  • 依托单位:
Progesterone Withdrawal/Tight Junction Closure--Pregnant
  • 批准号:
    6491075
  • 项目类别:
  • 资助金额:
    $15.0万
  • 财政年份:
    2001
  • 负责人:
    MARGARET Cobb NEVILLE
  • 依托单位:
海外基金